The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Open accessAbstract
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
JAK1 and JAK2 inhibitors have the potential to inhibit signaling downstream of type I interferon, interleukin-6 and other gp130 family receptors, interferon-γ, and interleukin-2, among other cytokines.
“JAK1 and JAK2 inhibitors, which are approved for the treatment of a number of autoimmune and neoplastic conditions, have the potential to inhibit signaling downstream of type I interferon, interleukin-6 (and other gp130 family receptors), interferon-γ, and interleukin-2, among other cytokines.107”
From Cytokine storm (2020) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works
Self-citationZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · see citing works
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415 · see citing works
Self-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148 · see citing works
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463 · see citing works
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · see citing works
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249 · see citing works
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,967 · see citing works
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621 · see citing works
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898 · see citing works
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775 · see citing works
Self-citationChannappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524 · see citing works
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,007 · see citing works
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,813 · see citing works
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701 · see citing works
Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,673 · see citing works
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456 · see citing works
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,391 · see citing works
Cytokine storm and sepsis disease pathogenesis
Chousterman, B. G., Świrski, F. K., & Weber, G. F. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0639-8 · Cited by 1,340 · see citing works
Understanding of COVID‐19 based on current evidence
Sun, P., Lu, X., Xu, C., Sun, W., & Pan, B. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25722 · Cited by 1,107 · see citing works
[A pathological report of three COVID-19 cases by minimal invasive autopsies].
Yao, X. H., Li, T. Y., He, Z. C., Ping, Y. F., Liu, H. W., Yu, S. C., Mou, H. M., Wang, L. H., Zhang, H. R., Fu, W. J., et al. (2020) · PubMed · doi:10.3760/cma.j.cn112151-20200312-00193 · Cited by 963 · see citing works
Self-citationDysregulation of Immune Response in Patients with COVID-19 in Wuhan, ChinaPreprint
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Yu, T., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3541136 · Cited by 898 · see citing works
Self-citationConti, P., Ronconi, G., Caraffa, A., Gallenga, C. E., Ross, R., Frydas, I., & Kritas, S. (2020) · Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents · doi:10.23812/conti-e · Cited by 643 · see citing works
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562 · see citing works
Self-citationChan, K. W., Wong, V. T., & Tang, S. C. W. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500378 · Cited by 396 · see citing works
New fronts emerge in the influenza cytokine storm
Guo, X.-Z. J., & Thomas, P. G. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0636-y · Cited by 295 · see citing works
Chen, C., Zhang, X., Ju, Z., & He, W. (2020) · PubMed · doi:10.3760/cma.j.cn501120-20200224-00088 · Cited by 277 · see citing works
Self-citationTreatment of Severe Acute Respiratory Syndrome With Glucosteroids
Chen, R.-C., Tang, X.-P., Tan, S.-Y., Bi-ling, L., Wan, Z. Y., Fang, J.-Q., & Zhong, N. (2006) · CHEST Journal · doi:10.1378/chest.129.6.1441 · Cited by 275 · see citing works
Mirabelli, C., Wotring, J. W., Zhang, C. J., McCarty, S. M., Fursmidt, R. M., Pretto, C. D., Qiao, Y., Zhang, Y., Frum, T., Kadambi, N. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105815118 · Cited by 218 · see citing works
Barnard, D. L., Day, C. W., Bailey, K. W., Heiner, M., Montgomery, R. A., Lauridsen, L., Chan, P. K. S., & Sidwell, R. W. (2006) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020601700505 · Cited by 210 · see citing works
Auyeung, T. W., Lee, J. S. W., Lai, W. K., Choi, C. H., Lee, H. K., Lee, J. S., Li, P. C. K., Lok, K. H., Yeung, Y. M., Wong, W. M., et al. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.09.008 · Cited by 208 · see citing works
High–Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome
Ho, J., OOI, G. C., Mok, T., Chan, J. W. M., Hung, I. F., LAM, B. K., Wong, P. C., Li, P. C., Ho, P., Lam, W. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200306-766oc · Cited by 208 · see citing works
Acidotropic amines inhibit proteolytic processing of flavivirus prM protein
Randolph, V. B., Winkler, G., & Stollar, V. (1990) · Virology · doi:10.1016/0042-6822(90)90099-d · Cited by 202 · see citing works
Clinical trial analysis of 2019‐nCoV therapy registered in China
Zhang, Q., Wang, Y., Qi, C., Shen, L., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25733 · Cited by 156 · see citing works
Predictors of fatality including radiographic findings in adults with COVID-19
Li, K., Chen, D., Chen, S., Feng, Y., Chang, C., Wang, Z., Wang, N., & Zhen, G. (2020) · Respiratory Research · doi:10.1186/s12931-020-01411-2 · Cited by 139 · see citing works
Hydroxychloroquine-Inhibited Dengue Virus Is Associated with Host Defense Machinery
Wang, L.-F., Lin, Y.-S., Huang, N., Yu, C.-Y., Tsai, W.-L., Chen, J., Kubota, T., Matsuoka, M., Chen, S.-R., Yang, C.-S., et al. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0038 · Cited by 127 · see citing works
Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease
Kumar, A., Liang, B., Aarthy, M., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01002 · Cited by 104 · see citing works
Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong
Yam, L. Y.-C., Lau, A. C.-W., Lai, F. Y.-L., Shung, E., Chan, J., & Wong, V. C. W. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.01.005 · Cited by 100 · see citing works
Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
Soliz, J., Gasser, E. M. S., Arias‐Reyes, C., Aliaga‐Raduán, F., Poma-Machicao, L., Zubieta-Calleja, G. R., Furuya, W. I., Trevizan‐Baú, P., Dhingra, R. R., & Dutschmann, M. (2020) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2020.103476 · Cited by 99 · see citing works
Akpovwa, H. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3182 · Cited by 88 · see citing works
Rubio, J. L. C., Castillo, J. D. D. L.-D., Fernández, J. D. L. H., Guirao‐Arrabal, E., Ruiz, M. C., & Ortego‐Centeno, N. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.07.002 · Cited by 54 · see citing works
Khalil, A., Kamar, A., & Nemer, G. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01248 · Cited by 44 · see citing works
Mechanisms of Myocardial Injury in Coronavirus Disease 2019
Rali, A. S., Ranka, S., Shah, Z. I., & Sauer, A. J. (2020) · Cardiac failure review · doi:10.15420/cfr.2020.10 · Cited by 37 · see citing works
Part I. SARS-CoV-2 triggered ‘PANIC’ attack in severe COVID-19
Frohman, E. M., Villemarette-Pittman, N. R., Melamed, E., Cruz, R. A., Longmuir, R. A., Varkey, T. C., Steinman, L., Zamvil, S. S., & Frohman, T. C. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116936 · Cited by 28 · see citing works
Lajoie, J., Mwangi, L. W., & Fowke, K. R. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0166-7 · Cited by 23 · see citing works
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
Mutti, L., Pentimalli, F., Baglìo, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01208 · Cited by 19 · see citing works
Lohse, A., Klopfenstein, T., Balblanc, J. C., et al. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.06.005 · Cited by 19 · see citing works
Callejas-Rubio, J. L., Millán, I. F. A., Higueras, M. M., Medina, L. M., López, M. L., & Torres, Á. C. (2020) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2020.05.004 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [25]Chen N. Zhou M. Dong X. Qu J. Gong F. Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 395 2020 507 513 32007143 PMC7135076
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J. M., Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J. S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200652 · Cited by 1,486 · see citing works
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476 · see citing works
Neurological Involvement in COVID-19 and Potential Mechanisms: A Review
Aghagoli, G., Gallo Marin, B., Katchur, N. J., Chaves-Sell, F., Asaad, W. F., & Murphy, S. A. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01049-4 · Cited by 357 · see citing works
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05275-1 · Cited by 251 · see citing works
Kadambari, S., Klenerman, P., & Pollard, A. J. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2144 · Cited by 118 · see citing works
The looming storm: Blood and cytokines in COVID-19
Kaur, S., Bansal, R., Kollimuttathuillam, S., Gowda, A. M., Singh, B., Mehta, D., & Maroules, M. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100743 · Cited by 113 · see citing works
Carubbi, F., Salvati, L., Alunno, A., Maggi, F., Borghi, E., Mariani, R., Mai, F., Paoloni, M., Ferri, C., Desideri, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83831-8 · Cited by 104 · see citing works
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98 · see citing works
Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection
Kesmez Can, F., Özkurt, Z., Öztürk, N., & Sezen, S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14970 · Cited by 66 · see citing works
Iglesias-Julián, E., López-Veloso, M., de-la-Torre-Ferrera, N., Barraza-Vengoechea, J. C., Delgado-López, P. D., Colazo-Burlato, M., Ubeira-Iglesias, M., Montero-Baladía, M., Lorenzo-Martín, A., Minguito-de-la-Iglesia, J., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102537 · Cited by 62 · see citing works
Agarwal, S., & June, C. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0473 · Cited by 30 · see citing works
- Authors
- Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., Zeng, X., & Zhang, S.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Yan, Xiaowei
- Zeng, Xiaofeng
- Zhang, Shuyang
- ORCID
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 214
- Pages
- 108393
- ISSN
- 1521-6616 (ISSN-L)
- PMC
- PMC7102614
- OpenAlex
- W3012655019
- Cited by
- 1,266
- References
- 48
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 57 · 2023: 93 · 2022: 167 · 2021: 364 · 2020: 561 · 2019: 1
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Basic Research Program of China (2016YFC0901500)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- COVID-19 pandemic, severe COVID-19, anti-inflammatory therapy, glucocorticoids, IL-6 receptor inhibitor, JAK inhibitors, chloroquine, hydroxychloroquine, immunosuppression, critically ill patients, multidisciplinary discussion
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Interleukin-6 Inhibitors, COVID-19 Drug Treatment, Anti-Inflammatory Agents, Chloroquine, Glucocorticoids, Humans, Hydroxychloroquine, Inflammation, Pneumonia, Viral, Thrombosis, Vasculitis, Interleukin-6, Cytokines, Coronavirus Infections, Janus Kinases, Pandemics, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
